Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 331 AL 345

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, Bittner T, Walsh DM, Selkoe DJ.

Ann Neurol. 2019 Aug;86(2):215-224. doi: 10.1002/ana.25513. Epub 2019 Jun 22.

Exosome-encapsulated microRNAs as promising biomarkers for Alzheimer's disease

Chen JJ, Yang G, Yan QQ, Zhao J, Li S.

Rev Neurosci. 2019 Dec 18;31(1):77-87. doi: 10.1515/revneuro-2019-0001.

The cellular and molecular processes associated with scopolamine-induced memory deficit: A model of Alzheimer's biomarkers

Tang KS.

Life Sci. 2019 Sep 15;233:116695. doi: 10.1016/j.lfs.2019.116695. Epub 2019 Jul 25.

Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

Müller EG, Edwin TH, Stokke C, Navelsaker SS, Babovic A, Bogdanovic N, Knapskog AB, Revheim ME.

PLoS One. 2019 Aug 20;14(8):e0221365. doi: 10.1371/journal.pone.0221365. eCollection 2019.

The "rights" of precision drug development for Alzheimer's disease

Cummings J, Feldman HH, Scheltens P.

Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.

Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE.

J Alzheimers Dis. 2019;71(3):715-732. doi: 10.3233/JAD-190507.

A Pilot Study of Exenatide Actions in Alzheimer's Disease

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D.

Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.

A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease

Provensi G, Carta F, Nocentini A, Supuran CT, Casamenti F, Passani MB, Fossati S.

Int J Mol Sci. 2019 Sep 24;20(19):4724. doi: 10.3390/ijms20194724.

Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer's Disease

Olasehinde TA, Olaniran AO, Okoh AI.

Mar Drugs. 2019 Oct 25;17(11):609. doi: 10.3390/md17110609.

Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang

Feygina EE, Katrukha AG, Semenov AG.

Biochemistry (Mosc). 2019 Nov;84(11):1346-1358. doi: 10.1134/S0006297919110105.

Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia

Chen JJ, Gong YH, He L.

J Drug Target. 2019 Apr;27(4):347-354. doi: 10.1080/1061186X.2018.1491979. Epub 2018 Jul 24.

Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease

Baig AM.

ACS Chem Neurosci. 2019 Jan 16;10(1):21-24. doi: 10.1021/acschemneuro.8b00409. Epub 2018 Aug 30.

Long-term medical costs of Alzheimer's disease: matched cohort analysis

Sopina E, Spackman E, Martikainen J, Waldemar G, Sørensen J.

Eur J Health Econ. 2019 Apr;20(3):333-342. doi: 10.1007/s10198-018-1004-0. Epub 2018 Aug 31.

Exosomes and microRNAs: New potential therapeutic candidates in Alzheimer disease therapy

Iranifar E, Seresht BM, Momeni F, Fadaei E, Mehr MH, Ebrahimi Z, Rahmati M, Kharazinejad E, Mirzaei H.

J Cell Physiol. 2019 Mar;234(3):2296-2305. doi: 10.1002/jcp.27214. Epub 2018 Sep 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias